Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Abraxis Provides Overview of ABRAXANE® Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium

Abstract:
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

Abraxis Provides Overview of ABRAXANE® Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium

Los Angeles, CA | Posted on December 8th, 2009

Clinical results from investigator-sponsored studies will be reported, including an ongoing study evaluating the combination of lapatinib and nab®-paclitaxel for first-line treatment of HER2+ breast cancer. Additional presentations will highlight analyses of cost of care in metastatic breast cancer patients, as well as the correlation between specific genotypes and treatment response rates.

ABRAXANE is currently approved in the second-line treatment of metastatic breast cancer and Abraxis continues to study the potential of ABRAXANE in areas of high unmet patient needs.

Metastatic breast cancer, also known as stage IV, refers to cancer that has spread to distant organs. In the majority of metastatic breast cancer patients, the metastasis is diagnosed after a cancer has already been treated. However, in about six to ten percent of all breast cancer patients, the cancer has spread to distant organs at the time of the first diagnosis. In the United States, there are 155,000 women and men living with metastatic breast cancer(i).

Results to be presented at the meeting include:

-A Taxane total cost of care analysis: Results of private payor claims data in metastatic breast cancer (Abstract #1076) Poster Presentation 1076; Thursday, December 10, 2009, 5:30 p.m. - 7:30 p.m.; Exhibit Halls A-B

-Pilot neoadjuvant trial with combination of lapatinib and nab®-paclitaxel in HER2+ breast cancer (Abstract #1091) Poster Presentation 1091; Thursday, December 10, 2009, 5:30 p.m.-7:30 p.m.; Exhibit Halls A-B

-The basal-like, luminal-like, and HER2-like genotype and the 70-gene signatures predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab®-paclitaxel and carboplatin +/- trastuzumab (trast) as part of (NCT) in patients (pts) with stage II-III breast cancer [including inflammatory breast cancer (BC)]. (Abstract #2026) Poster Presentation 2026; Friday, December 11, 2009, 7:00 a.m. - 9:00 a.m., Exhibit Halls A-B

iMetastatic Breast Cancer Network, www.mbcnetwork.org/page.aspx?nm=mainpage Accessed November 2009.

####

About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab®platform. The first FDA approved product to use this nab®platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab®platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.

About ABRAXANE

ABRAXANE® is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience's proprietary nab® technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin, a naturally occurring human protein. By wrapping the albumin around the active drug, ABRAXANE can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel. ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: expanded applications for metastatic breast, non-small cell lung, malignant melanoma, pancreatic and gastric.

The U.S. Food and Drug Administration approved ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The U.S. Food and Drug Administration granted orphan-drug designation for ABRAXANE for the treatment of pancreatic cancer in September 2009 and stage IIb to IV melanoma in October 2009. For the full prescribing information for ABRAXANE please visit www.abraxane.com.


For more information, please click here

Contacts:
Investors and Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
310-883-1300


Media Inquiries
Victoria Fort
202-361-0445

Copyright © Abraxis BioScience

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Events/Classes

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Iran-Made Respiratory Nano Masks Provided to Hajj Pilgrims October 23rd, 2014

MEMS & Sensors Technology Showcase: Finalists Announced for MEMS Executive Congress US 2014 October 23rd, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Nanobiotechnology

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE